Recent Posts
- 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
- Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
- Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
- Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
- Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.